UOC
CYTO

UBS O'Connor’s Altamira Therapeutics Ltd CYTO Stock Holding History

UBS O'Connor’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10
Closed -$575K – 464
2017
Q2 		$575K Sell
10
-2
-17% -$113K 0.01% 334
2017
Q1 		$909K Buy
+12
New +$962K 0.02% 341

Other funds holding CYTO

SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return

UBS O'Connor's CYTO Position: Q3 2017 in Review

UBS O'Connor sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2017, closing a stake of 10 shares — an estimated $575K sold.

UBS O'Connor first reported a position in CYTO in Q1 2017 and held it in 2 quarters. The position peaked at $909K in Q1 2017. 7 funds tracked by Wall St. Rank hold CYTO as of Q3 2017.

  • UBS O'Connor reported no remaining Altamira Therapeutics Ltd position as of Q3 2017 after selling out during the quarter.
  • UBS O'Connor sold 10 Altamira Therapeutics Ltd shares in Q3 2017, an estimated $575K.
  • UBS O'Connor first reported a position in Altamira Therapeutics Ltd in Q1 2017 and held it in 2 quarters.
  • UBS O'Connor's Altamira Therapeutics Ltd position peaked at $909K in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2017.

Based on UBS O'Connor's 13F filing for Q3 2017, filed 14 Nov 2017.